STEMCELL INSTITUTE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,676 JPY | +0.48% |
|
-0.18% | -21.83% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
Weaknesses
- With an expected P/E ratio at 44.96 and 34.18 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.83% | 109M | - | ||
| +26.08% | 89.38B | C+ | ||
| -23.66% | 75.67B | B- | ||
| +8.59% | 28.83B | C+ | ||
| +5.95% | 18.25B | A- | ||
| -13.80% | 16.51B | B | ||
| +2.60% | 15.72B | A- | ||
| +78.26% | 13.71B | C- | ||
| +82.29% | 13.46B | C+ | ||
| +3.93% | 12.4B | A- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 7096 Stock
- Ratings StemCell Institute Inc.
